ProCE Banner Activity

Long-term Follow-up of CD19-Targeted CAR-T Cells (CTL019) in Pediatric Patients With Relapsed/Refractory ALL

Slideset Download
Conference Coverage
Potent and durable antitumor activity seen in pediatric patients with relapsed/refractory ALL.

Released: December 13, 2015

Expiration: December 11, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen